EP1139751A4 - EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS - Google Patents

EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS

Info

Publication number
EP1139751A4
EP1139751A4 EP99967703A EP99967703A EP1139751A4 EP 1139751 A4 EP1139751 A4 EP 1139751A4 EP 99967703 A EP99967703 A EP 99967703A EP 99967703 A EP99967703 A EP 99967703A EP 1139751 A4 EP1139751 A4 EP 1139751A4
Authority
EP
European Patent Office
Prior art keywords
cardiomyocytes
vivo
efficient
stable
gene transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP99967703A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1139751A1 (en
Inventor
Jeffrey M Leiden
Eric Svensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp filed Critical Arch Development Corp
Publication of EP1139751A1 publication Critical patent/EP1139751A1/en
Publication of EP1139751A4 publication Critical patent/EP1139751A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99967703A 1998-12-28 1999-12-28 EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS Ceased EP1139751A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11392398P 1998-12-28 1998-12-28
US113923P 1998-12-28
PCT/US1999/031093 WO2000038518A1 (en) 1998-12-28 1999-12-28 Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors

Publications (2)

Publication Number Publication Date
EP1139751A1 EP1139751A1 (en) 2001-10-10
EP1139751A4 true EP1139751A4 (en) 2003-03-19

Family

ID=22352321

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99967703A Ceased EP1139751A4 (en) 1998-12-28 1999-12-28 EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS

Country Status (5)

Country Link
EP (1) EP1139751A4 (https=)
JP (1) JP2002533359A (https=)
AU (1) AU763049B2 (https=)
CA (1) CA2356551A1 (https=)
WO (1) WO2000038518A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
CA2389524A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
CA2419245A1 (en) * 2000-08-17 2002-02-21 Keiya Ozawa Adeno-associated virus-mediated delivery of angiogenic factors
EP1870473A1 (en) * 2000-08-17 2007-12-26 Keiya Ozawa Adeno-associated virus-mediated delivery of angiogenic factors
EP1324780A4 (en) 2000-09-06 2005-06-22 Univ Johns Hopkins METHODS OF TREATING CARDIAC ARRHYTHMIA
WO2002098432A1 (en) * 2001-06-01 2002-12-12 The Brigham And Women's Hospital, Inc. Methods of treating cardiac disorders
AU2003299204A1 (en) 2002-10-02 2004-04-23 The Johns Hopkins University Focal calcium channel modulation
US20070134204A1 (en) * 2005-12-09 2007-06-14 Henrich Cheng Method for treating nerve injury and vector construct for the same
KR20090035711A (ko) * 2006-07-25 2009-04-10 셀라돈 코포레이션 유전자 치료를 위한 아데노-관련 바이러스 벡터의 전방 심외막 관상에의 연장 주입
KR20100129295A (ko) 2008-02-19 2010-12-08 셀라돈 코포레이션 심근 내 바이러스 벡터의 흡수를 개선시키기 위한 조성물
AU2012258525B2 (en) * 2011-05-26 2017-02-23 University Of Washington Cell and gene based methods to improve cardiac function
WO2019097001A1 (en) * 2017-11-16 2019-05-23 Universite D'aix-Marseille Fgf10 for the treatment of heart diseases
US12460226B2 (en) 2018-04-16 2025-11-04 The Trustees Of The University Of Pennsylvania Compositions and methods for treating duchenne muscular dystrophy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012050A1 (en) * 1995-09-27 1997-04-03 The Rockefeller University Method for transferring genes to the heart using aav vectors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792483A (en) * 1993-04-05 1998-08-11 Vickers, Inc. Injection molding machine with an electric drive

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012050A1 (en) * 1995-09-27 1997-04-03 The Rockefeller University Method for transferring genes to the heart using aav vectors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KESSLER P D ET AL: "SODIUM BUTYRATE GREATLY ENHANCES THE EFFICIENCY OF VIRAL TRANSDUCTION IN ADULT VENTRICULAR CARDIOMYOCYTES BY ADENO-ASSOCIATED VIRAL VECTORS", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 92, no. 8, 15 October 1995 (1995-10-15), pages 1408, XP000673503, ISSN: 0009-7322 *
MAEDA ET AL: "Efficient Gene Transfer into Cardiac Myocytes Using Adeno-Associated Virus (AAV) Vectors", J MOL CELL CARDIOL, vol. 30, July 1998 (1998-07-01), pages 1341 - 1348 *
See also references of WO0038518A1 *

Also Published As

Publication number Publication date
WO2000038518A1 (en) 2000-07-06
AU763049B2 (en) 2003-07-10
WO2000038518A9 (en) 2002-04-11
CA2356551A1 (en) 2000-07-06
EP1139751A1 (en) 2001-10-10
JP2002533359A (ja) 2002-10-08
AU2394200A (en) 2000-07-31

Similar Documents

Publication Publication Date Title
FR2727867B1 (fr) Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
EP1139751A4 (en) EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS
IL132673A0 (en) Gene transfer with adenoviruses having modified fiber proteins
WO2000020557A3 (en) GEMINIVIRUS VECTORS FOR GENE EXPRESSION IN PLANTS
EP0981649A4 (en) PEPTIDES THAT IMPROVE THE TRANSPORT OF AN ACTIVE ACTIVE SUBSTANCE THROUGH TISSUES, AND COMPOSITIONS AND METHODS USING THE SAME
IL131209A0 (en) Recombinant haloaliphatic dehalogenases
ZA989012B (en) Chlamydia protein gene sequence and uses thereof
FI964172A7 (fi) Geenin ilmentymisjärjestelmä in vivo
AU5464000A (en) Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
IT1291135B1 (it) Vettori ricombinanti utilizzabili in terapia genica
FR2818481B1 (fr) Teletraitement et distribution d'images dans des kiosques
ATE327337T1 (de) Verbesserungen der spezifität der genexpression
EP1207198A4 (en) G-PROTEIN COUPLED RECEPTOR PROTEIN AND ITS DNA
FR2755699B1 (fr) Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes
EP1186615A4 (en) PROTEIN AND DNA OF THIS PROTEIN
IL117466A0 (en) Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy
FR2769276B1 (fr) Articulation d'accouplement
HUP0003327A3 (en) Grapevine leafroll virus (type 2) proteins and their uses
IT9020072A0 (it) Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
EP1064947A4 (en) IN OVO VACCINATION AGAINST MAREK'S DISEASE VIRUS, TYPE 1
FR2759708B1 (fr) Moyens pour identifier, isoler et caracteriser des sequences nucleotidiques impliquees dans l'apomixie
EP1162887A4 (en) GENE TRANSFER BY RECOMBINANT ADENO-ASSOCIATED VIRUS INFLUENCING DEMYELINIZATION
EP1124840A4 (en) GENES AND PROTEINS SPECIFIC TO OVARIES
FR2766145B1 (fr) Attache de levage et groupe moto-propulseur equipe d'une telle attache
EP1181316A4 (en) DNA WHICH CODES FOR SNORF36A AND SNORF36B RECEPTORS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010726

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030204

17Q First examination report despatched

Effective date: 20031103

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20090312